Business context and reporting period
The supplied filing is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019—not a filing identified as Cervomed Inc. Diffusion is a clinical-stage biotechnology company with no product-sales revenue. Its lead candidate, TSC, is being developed for hypoxia-related conditions, including inoperable glioblastoma and acute stroke; it is also evaluating options for RES-529.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $1.70 million | $1.83 million; down $0.13 million |
| General and administrative expense | $1.20 million | $1.50 million; down $0.30 million |
| Operating loss | $2.92 million | $3.35 million |
| Net loss | $2.75 million | $3.31 million |
| Net loss per share | $0.81 | $4.11 attributable to common stockholders |
| Cash used in operating activities | $2.66 million | $3.29 million |
| Cash and cash equivalents | $5.33 million at March 31 | $7.99 million at December 31, 2018 |
| Working capital | $5.19 million at March 31 | Not stated for the comparable date |
There are no operating margins to assess because the company reported no revenue. Total assets were $15.99 million and total liabilities $3.03 million at March 31. The filing reports no credit facilities or committed sources of capital; it does not identify material borrowings. Quarterly cash declined by $2.66 million, and management expected available cash to fund operations into July 2019.
Material changes versus the prior comparable period
Operating expenses fell by approximately $0.43 million year over year. Management attributed the R&D decrease mainly to $0.5 million lower spending on the Phase 3 GBM trial, partly offset by $0.4 million of increased spending as the stroke program commenced. G&A declined $0.3 million, reflecting lower salaries and stock-based compensation. Net loss improved by $0.57 million, including a $0.15 million income tax benefit in 2019. Q1 2018 common-stockholder loss and loss per share were elevated by a $8.17 million deemed dividend related to the preferred-stock make-whole conversion provision and $0.09 million in preferred dividends; these were not recurring Q1 2019 charges. The company raised no financing in Q1 2019, compared with $10.59 million of net financing cash in Q1 2018.
Outlook, risks and unusual items
- Funding and going concern: The company has incurred recurring losses, expects substantial future losses, and states that substantial doubt exists about its ability to continue as a going concern. Additional financing is needed; none is assured. Failure to raise funds could force delays, reductions or termination of programs, strategic transactions, or cessation of operations.
- Clinical plans: The eight-patient INTACT Phase 3 GBM safety run-in was expected to finish in Q2 2019. Starting the 236-patient randomized phase was contingent on a strategic partnership providing resources. The company expected first enrollment in its 160-patient PHAST-TSC Phase 2 stroke trial in Q3 2019, subject to institutional review and contracting. Timelines and plans are forward-looking and funding-dependent.
- Other risks: Clinical and regulatory outcomes, ability to recruit and retain personnel, third-party research/manufacturing performance, intellectual-property protection, competition, Nasdaq listing and future financing terms pose risks. Equity or convertible financing could dilute existing holders or alter security rights.
- Legal contingency: A former CEO’s arbitration matter was scheduled for November 2019. The company says it believes the matter is without merit, but could not estimate the outcome or any loss range; it noted a possible material effect on financial position.
- Accounting and capital structure: Adoption of lease accounting in Q1 recognized a $0.3 million right-of-use asset and corresponding lease liability, without affecting operations or cash flows upon adoption. At March 31, 2.09 million warrants were outstanding; potential dilution is excluded from diluted loss per share as anti-dilutive. Shares and per-share amounts reflect the December 2018 1-for-15 reverse split.
Most important facts for investors to verify
- Whether the company raised financing after March 31, 2019 and how long its cash runway actually lasted.
- Whether the GBM safety run-in was completed and whether a strategic partner enabled the randomized Phase 3 trial.
- Whether PHAST-TSC began enrollment on the expected schedule and whether trial funding remained adequate.
- Any subsequent developments, estimated exposure or resolution in the former CEO arbitration.
- Current share count, warrant terms and potential dilution from future equity or convertible financing.